SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15 (d) OF
THE
SECURITIES EXCHANGE ACT OF 1934
Date
of
Report (Date of earliest event reported): March 31, 2006
SIGA
TECHNOLOGIES, INC.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
0-23047
|
13-3864870
|
|
(State
or other jurisdiction of
incorporation
or organization)
|
(Commission
file number)
|
(I.R.S.
employer
identification
no.)
|
|
420
Lexington Avenue, Suite 408
New
York, New York
(Address
of principal executive offices)
|
10170
(Zip
code)
|
Registrant’s
telephone number, including area code: (212) 672-9100
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see
General
Instruction A.2. below):
r
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
r
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
r
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
r
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item
1.01. Entry
Into a Material Definitive Agreement.
In
anticipation of the closing of the proposed merger with Pharmathene, Inc.,
announced March 14, 2006, SIGA Technologies, Inc., a Delaware corporation
(“SIGA”) and Dr. Bernard L.
Kasten, its Chief Executive Officer, today announced Dr. Kasten’s agreement to
resign his employment with SIGA, effective the earlier of April, 30 2006 or
Dr.
Kasten’s obtaining new employment (the “Remaining Tenure”). In connection with
such agreed upon resignation, SIGA and Dr. Kasten entered into a Separation
Agreement dated March 31, 2006 (the “Separation Agreement”). The following
summary of certain provisions of the Separation Agreement is qualified in its
entirety by reference to the complete Separation Agreement, a copy of which
is
filed as Exhibit 10.1 hereto.
Through
September 16, 2006 (the “Separation Period”), Dr. Kasten will receive his salary
on the existing terms and conditions as set forth in his Employment Agreement
with SIGA, dated July 2, 2004 (the “Employment Agreement”) in lieu of any other
severance or payment. Concurrently with the execution of the Separation
Agreement, SIGA and Dr. Kasten are also amending Dr. Kasten’s Incentive Stock
Option Agreement such that Dr. Kasten’s “Milestone Options” (as such term is
defined in the Employment Agreement) are cancelled and Dr. Kasten’s “Time Vested
Options” (as such term is defined in the Employment Agreement) are amended such
that with respect to the Time Vested Options which have not vested as of the
date of the Separation Agreement, such options will vest as follows: with
respect to 166,666 shares as of July 2, 2006 and with respect to the remaining
83,334 shares, as of January 2, 2007. Time Vested Options granted to Dr. Kasten
which have vested prior to the date of the Separation Agreement shall remain
unchanged.
Dr.
Kasten will also be permitted to continue to receive medical and/or dental
insurance benefits under the relevant SIGA plans until (i) the end of the
Remaining Tenure, (ii) he becomes entitled to Medicare or (iii) he becomes
eligible for coverage under medical and/or dental insurance benefit plans,
as
the case may be, of another employer through his future employment, whichever
occurs first.
The
Separation Agreement also contains mutual non-disparagement and release terms,
requires that Dr. Kasten remain available to SIGA on a reasonable basis for
transitional purposes during the Separation Period and requires SIGA to
indemnify Dr. Kasten under the terms of its certificate of incorporation and
bylaws for acts relating to his employment.
Item
1.02. Termination
of a Material Definitive Agreement.
See
Item
1.01 above for a description of the terms of the Separation Agreement, which,
among other things, terminates the Employment Agreement. A copy of the
Employment Agreement was included as Exhibit 10.1 to SIGA’s Quarterly Report on
Form 10-QSB filed on August 16, 2004 and the description of the Employment
Agreement above does not purport to be complete and is qualified in its entirety
by reference to the filed Employment Agreement.
|
Item
5.02.
|
Departure
of Directors or Principal Officers; Election of Directors; Appointment
of
Principal Officers.
|
See
Item
1.02 above for a description of Dr. Kasten’s agreement to resign his employment
with SIGA, effective the earlier of April, 30 2006 or Dr. Kasten’s obtaining new
employment, which is incorporated by reference in this Item 5.02.
Effective
immediately upon the expiration of the Remaining Tenure, Thomas N. Konatich
(“Konatich”), currently SIGA’s Chief Financial Officer, will be appointed to
serve in an additional capacity as Acting
Chief
Executive Officer of SIGA until such point as the board of directors of SIGA
shall select a permanent Chief Executive Officer. Additional information about
Konatich and his employment agreement with SIGA is incorporated by reference
from SIGA’s Definitive Proxy Statement on Schedule 14A filed on April 29, 2005
and Annual Report on Form 10-K filed on March 29, 2006.
On
April
3, 2006, SIGA issued a press release announcing Dr. Kasten’s agreement to resign
his employment with SIGA and Konatich’s designation to replace Dr. Kasten as
Acting Chief Executive Officer. A copy of the press release is attached hereto
as Exhibit 99.1, which is incorporated by reference in this Item
5.02.
Item
9.01. Financial Statements and Exhibits.
(c)
Exhibits
|
Exhibit
No.
|
Description
|
|
10.1
|
Separation
Agreement between SIGA and Dr. Bernard Kasten, dated March 31,
2006.
|
|
99.1
|
Press
Release dated April 3, 2006
|
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
SIGA
TECHNOLOGIES, INC.
By:
/s/
Thomas N.
Konatich
Name:
Thomas
N.
Konatich
Title:
Chief
Financial Officer
Date: April
3,
2006
Exhibit
10.1
SEPARATION
AGREEMENT
This
Separation Agreement (the “Agreement”) is entered into as of March 31, 2006,
between SIGA Technologies, Inc., a Delaware corporation (the “Company”), and
Bernard Kasten, M.D. (“Executive”).
WHEREAS,
the
Company no longer desires to employ Executive and Executive no longer desires
to
be employed by the Company, the parties hereto agree to terminate Executive’s
employment on the terms and conditions set forth herein.
NOW,
THEREFORE, in
consideration of the foregoing premises and of the mutual agreements and
covenants hereinafter set forth, the parties agree to the terms and conditions
of this Agreement as follows:
|
1.
|
EMPLOYMENT
AGREEMENT TERMINATED.
Except as otherwise expressly set forth below, all terms and conditions
of
the Employment Agreement dated July 2, 2004 between Executive and
Company
(the “Employment Agreement”) are hereby terminated, and this Agreement and
its attachment expressly
supersede any and all previous understandings and agreements between
the
Company and Executive and constitute the sole and exclusive understanding
between the Company and Executive concerning the subjects set forth
herein.
|
|
2.
|
REMAINING
TENURE.
Executive shall retain the title of Chief Executive Officer (“CEO”)
through and including April 30, 2006 or until he obtains new employment,
whichever occurs first (the “Remaining Tenure”).
|
|
3.
|
CONSIDERATION.
|
|
a.
|
Salary.
During the Remaining Tenure and for an additional period beginning
the
first business day after the end of the Remaining Tenure and continuing
through September 16, 2006 (the “Separation Period”), Executive shall
receive his salary on the terms and conditions set forth in Section
3(a)
of the Employment Agreement in lieu of any other severance or payment.
|
|
b.
|
Options.
Concurrently with the execution of this Agreement, the parties will
execute an amendment to Executive’s Incentive
Stock Option Agreement (relating to the “Time Vested Options,” as such
term is defined in the Employment Agreement)
that is substantially in the form of the annexed Exhibit A. Executive’s
Incentive Stock Option Agreement (relating to the “Milestone Options,” as
such term is defined in the Employment Agreement) is cancelled and
hereby
declared void ab
initio
and of no further force or effect. The parties’ rights and obligations
with respect to all options in Company stock, whether vested or unvested,
shall be as set forth in the amended Incentive Stock Option Agreement
(relating to the Time Vested
|
|
|
Options),
notwithstanding anything in the Employment
Agreement to the contrary.
|
c.
|
Medical
and/or Dental Insurance Benefits.
Executive will be permitted to continue participation in the Company's
group medical and/or dental insurance benefit plans as in effect
and
amended from time to time at the contribution level in effect for
active
employees until (i) the end of the Remaining Tenure, (ii) he becomes
entitled to Medicare or (iii) he becomes eligible for coverage under
medical and/or dental insurance benefit plans, as the case may be,
of
another employer through his future employment, whichever occurs
first.
Executive shall notify the Company of his eligibility for coverage
under
medical and/or dental insurance benefit plans of any future employer
of
Executive promptly and no later than the date when such coverage
begins.
|
|
4.
|
COOPERATION.
During the Remaining Tenure and Separation Period, Executive shall
be
available to the Company on a reasonable basis for transitional purposes,
including, but not limited to, working on continuing funding projects,
the
proposed transaction between the Company and PharmAthene, Inc., Company
obligations with respect to the Securities and Exchange Commission
(“SEC”)
and the transition of contacts developed in connection with Executive’s
work as CEO. At any time, upon request, Executive shall give his
assistance and cooperation willingly in any matter relating to his
expertise or experience as the Company may reasonably request, including
his attendance and truthful testimony where deemed appropriate by
the
Company, with respect to any investigation or the Company's defense
or
prosecution of any existing or future claims or litigations relating
to
matters in which he was involved or potentially has knowledge by
virtue of
his employment with the Company.
|
|
5.
|
NON-DISPARAGEMENT.
Executive will not disparage or defame the Company, its employees,
officers, directors or shareholders, any of its actual or proposed
products or services, the proposed combination of the Company and
PharmAthene, Inc. or any other activity of the Company during his
tenure
with the Company. The Company will not disparage or defame Executive.
The
parties acknowledge that providing substantially accurate information
concerning Executive’s period of tenure or job titles with the Company
shall not violate this Agreement.
|
|
6.
|
ANNOUNCEMENT
OF SEPARATION.
The parties shall work in good faith to craft a mutually acceptable
public
announcement concerning the subject of this Agreement, including
a press
release and Company disclosure on SEC Form
8-K.
|
|
7.
|
OUT-OF-POCKET
EXPENSES.
During the Remaining Tenure and Separation Period, Executive shall
be
reimbursed for all legitimate out-of-pocket expenses actually incurred
in
connection with his cooperation with the Company pursuant to Paragraph
4
of this Agreement, so long as such expenses are approved in advance
and
substantiated with appropriate
receipts.
|
2
| 8. |
COMPANY
PROPERTY.
At the end of the Remaining Tenure, Executive shall return all Company
property in his possession or control, including, without limitation,
computer disks or data (including, without limitation, data retained
on
any computer), any home-office equipment or computers purchased or
provided by the Company, and any records, documents, files or other
materials. Executive may retain the computer monitor and other devices
without data storage capabilities previously supplied or made available
to
him that have never contained Company data if, within seven (7) days
of
the execution of this Agreement, he shall remit to the Company the
full
purchase cost of such items.
|
|
9.
|
INDEMNIFICATION.
Executive shall remain entitled to indemnification from the Company
under
the terms of the Company’s certificate of incorporation and bylaws as in
effect on
the date of this Agreement for acts relating to his employment by
the
Company. Without limiting the foregoing, the Company agrees to indemnify
Executive in accordance with the Company’s certificate of incorporation
and bylaws in connection with the claims arising out of the pending
litigation with Four Star Group without Executive being required
to make
any further demand or notice, effective on the receipt by the Company
of
Executive’s undertaking.
|
| 10. |
RELEASES.
|
|
(a)
|
RELEASE
OF COMPANY.
Executive hereby releases and holds harmless (on behalf of himself
and his
family, heirs, executors, agents, successors and assigns) now and
forever,
the Company from and waives any claim in any legal jurisdiction that
he
has presently or may have or has had in the past, known or unknown,
against the Company upon or by reason of any matter, cause or thing
whatsoever, from the beginning of the world to the date of this release,
including, without limitation, all claims arising from his employment
with, or termination of employment from, the Company, or otherwise.
Without limiting the generality of the preceding, this Agreement
is
intended to and shall release the Company from any and all claims
or
rights arising under any federal, state or local statute (including,
without limitation, Title VII of the Civil Rights Act of 1964, as
amended,
the Age Discrimination in Employment Act of 1967, as amended, the
Equal
Pay Act, as amended, the Americans with Disabilities Act of 1990,
as
amended, the Employee Retirement Income Security Act of 1974, as
amended,
the Family and Medical Leave Act of 1993, as amended, the Fair Labor
Standards Act, as amended, and all other statutes regulating the
terms and
conditions of your employment), regulation or ordinance, under the
common
law or in equity (including any claims for wages, wrongful discharge,
discrimination, or otherwise), or under any policy, agreement,
understanding or promise, written or oral, formal or informal, between
the
Company and Executive, including, without limitation, any claim Executive
might have for severance, termination or severance pay. Notwithstanding
the provision of any state law, and for the purpose of implementing
a full
and complete release and discharge of the Company, Executive expressly
acknowledges that this Agreement is intended to include in its effect,
without limitation, all claims which Executive does not
know
|
3
of
or
suspect to exist in his favor at the time of signing this Agreement and arising
from his employment with or termination of employment from the Company, and
that
this Agreement contemplates the release of any such claim.
|
(b)
|
COVENANT
NOT TO SUE.
Executive will not sue the Company’s shareholders, or the officers,
directors, employees, agents, attorneys, successors or assigns of
any of
the Company or its shareholders (collectively, with the Company’s
shareholders, the “Company-Related Group”), regarding any claim or matter
relating to or arising out of Executive’s employment with the Company, the
termination of Executive’s employment, or any other event or activity
relating or pertaining to the Company; provided,
however,
that the covenant set forth in this Paragraph 10(b) shall not bar
the
assertion of any defense or counterclaim to any claim brought by
any
member of the Company-Related Group. Executive acknowledges that
all
members of the Company-Related Group are intended third-party
beneficiaries of this covenant.
|
|
(c)
|
RELEASE
OF EXECUTIVE.
The Company hereby releases and holds harmless (on behalf of itself
and
its agents, successors and assigns) now and forever, the
Executive (and
his family, heirs, executors, agents, successors and assigns) from,
and
waives any claim in any legal jurisdiction that it has presently
or may
have or has had in the past, known or unknown, against, the Executive
upon
or by reason of any matter, cause or thing whatsoever, from the beginning
of the world to the date of this release, including, without limitation,
all claims arising from the Executive’s employment with, or termination of
employment from, the Company, or
otherwise.
|
|
(d)
|
STOCK
OPTION AGREEMENT NOT RELEASED.
The releases set forth in this Paragraph 10 do not extend to the
rights
and obligations set forth in this Agreement or the amended Incentive
Stock
Option Agreement.
|
|
11.
|
CONFIDENTIALITY,
INVENTION OWNERSHIP AND RELATED COVENANTS.
Executive shall remain bound by the obligations contained in Section
8(a),
8(b) and 8(c) of the Employment Agreement. In addition, Executive
shall
not at any time divulge to any other entity or person any confidential
information acquired by Executive concerning the Company’s or its
affiliates’ financial affairs or business processes or methods or their
research, development or marketing programs or plans, any other of
its or
their trade secrets, any information regarding personal matters of
any
directors, officers, employees or agents of the Company or their
respective family members, any information concerning this Agreement
or
the terms thereof, or any information concerning the circumstances
of
Executive’s employment with and any termination of Executive’s employment
from the Company, or any information regarding discussions related
to any
of the foregoing or make, write, publish, produce or in any way
participate in placing into the public domain any statement, opinion
or
information with respect to any of the foregoing or that reflects
adversely upon or would reasonably impair the reputation or best
interests
of the Company or any of its directors, officers, employees or agents
or
their
|
4
respective
family members, except in each case (i) information that is required to be
disclosed by court order, subpoena or other judicial process,
(ii) information regarding Executive’s job responsibilities during his
employment with the Company to prospective employers in connection with an
application for employment, (iii) information regarding the financial terms
of
this Agreement to Executive’s spouse or his tax advisor for purposes of
obtaining tax advice provided that such persons are made aware of and agree
to
comply with the confidentiality obligation, (iv) information that is necessary
to be disclosed to Executive’s attorney to determine whether Executive should
enter into this Agreement or (v) information mutually agreed upon pursuant
to
Paragraphs 4 or 6 of this Agreement. The foregoing prohibitions shall include,
without limitation, directly or indirectly publishing (or causing, participating
in, assisting or providing any statement, opinion or information in connection
with the publication of) any diary, memoir, letter, story, photograph,
interview, article, essay, account or description (whether fictionalized or
not)
concerning any of the foregoing, publication being deemed to include any
presentation or reproduction of any written, verbal or visual material in any
communication medium, including any book, magazine, newspaper, electronic or
internet publication or discussion group, theatrical production or movie, or
television or radio programming or commercial. In addition to any and all other
remedies available to the Company for any violation of this Paragraph, Executive
agrees to immediately remit and disgorge to the Company any and all payments
paid or payable to him in connection with or as a result of engaging in any
of
the above acts. In the event that Executive is required to make disclosure
under
any court order, subpoena or other judicial process that in any way relates
to
his employment with the Company or any of the foregoing matters described above,
Executive will promptly notify the Company so that the Company may seek
appropriate relief from such disclosure or waive Executive’s duty of
nondisclosure hereunder, provided that, if, following any such effort by the
Company to avoid disclosure, Executive shall, in the reasonable opinion of
his
counsel, stand liable for contempt or suffer other censure or penalty for
failure to disclose, Executive may make such disclosure under terms that seek
to
protect confidentiality to the extent permissible without liability hereunder.
Executive shall permit the Company to participate with counsel of its choice
in
any proceeding relating to such compulsory disclosure and shall cooperate with
the Company’s efforts to avoid disclosure. Executive acknowledges that all
information the disclosure of which is prohibited by this Paragraph is of a
confidential and proprietary character and of great value to the
Company.
|
12.
|
FREE
WILL.
Executive is entering into this Agreement of his own free will and
without
coercion, intimidation or threat of retaliation. He acknowledges
and
agrees that the Company has not exerted any undue pressure or influence
on
him in this regard. Executive acknowledges that he has had reasonable
time
to determine whether entering into this Agreement is in his best
interest,
has retained counsel and has read and fully understands the terms
set
forth in this Agreement.
|
|
13.
|
PENALTIES.
If Executive initiates or participates (other than as a witness providing
truthful testimony or relevant documents in his possession or control,
subject to Section 11 of this Agreement) in any lawsuit or other
legal
action arising out of his
employment
|
|
|
5
with
the
Company or the termination of his employment with the Company, the Company
may,
except as otherwise prohibited by law, reclaim any and all amounts paid under
Section 3(a), 3(c) or 7 of this Agreement, without waiving the release granted
herein, and terminate any unpaid or unvested benefit or payment that is due
under this Agreement, in addition to any other remedies it may have. In
addition, in any action brought to enforce this Agreement, the prevailing party
shall be entitled to receive all of its reasonable attorneys’ fees and costs
incurred resulting from, or incident to, any such litigation.
|
14.
|
NOTICE.
Any notice to be given under this Agreement shall be given in writing
and
delivered either personally or sent by certified mail to the Company
c/o
Chief Financial Officer at 420 Lexington Avenue, Suite 408, New York,
New
York 10170, and to you at 4380 27th
Court, S.W., Building No. One, #104, Naples, Florida 34116, with
a copy to
Bradley G. Haas, Esq., Katz Teller Brant & Hild, 255 East Fifth
Street, Suite 2400, Cincinnati, OH
45202.
|
|
15.
|
NON-ADMISSION.
Nothing contained in this Agreement shall be deemed or construed
as an
admission of wrongdoing or liability on the part of the Company or
Executive.
|
|
16.
|
SEVERABILITY.
Should any provision or part of this Agreement be found to be invalid
or
unenforceable, only that particular provision or part so found and
not the
entire agreement shall be
inoperative.
|
|
17.
|
ASSIGNMENT.
This Agreement may be assigned by the Company to (i) any affiliate
of the
Company or (ii) any non-affiliate of the Company that shall acquire
all or
the greater part of the business and assets of the Company. In the
event
of any such assignment, the Company shall cause such affiliate or
non-affiliate, as the case may be, to assume the obligations of the
Company hereunder with the same effect as if such assignee were the
“Company” hereunder. This Agreement is personal to Executive and Executive
may not assign any rights or delegate any responsibilities hereunder
without the prior approval of the
Company.
|
|
18.
|
NON-ALIENATION.
Executive shall not have any right to pledge, hypothecate or in any
way
create a lien upon any payment or benefit provided under this Agreement,
and no such payment or benefit shall be assignable in anticipation
of
payment, either by voluntary or involuntary acts or by operation
of
law.
|
|
19.
|
GOVERNING
LAW AND CHOICE OF FORUM.
This Agreement shall be governed by, and construed pursuant to, the
laws
of the State of New York applicable to agreements made and to be
performed
in New York by citizens thereof. The parties consent and agree to
the
exclusive jurisdiction of the federal and state courts sitting in
the
County of New York in the State of New York for all purposes. Notice
of
any lawsuit may, but need not, be sent in accordance with Paragraph
14
above in lieu of any other allowable
method.
|
6
| 20. |
ENTIRE
AGREEMENT.
This Agreement and its attachment constitute the sole and exclusive
understanding between the Company and Executive concerning the subjects
set forth herein, other than the surviving terms of the Employment
Agreement and the amended Incentive Stock Option Agreement (relating
to
Time Vested Options) expressly referenced herein or in the attachment,
the
terms of which remain in full force and effect. Neither this Agreement
nor
the attachment may be altered, modified, changed or discharged except
in a
writing signed by Executive and agreed to by the
Company.
|
IN
WITNESS WHEREOF,
the
parties hereto have executed this Agreement as of the date first written
above.
SIGA
TECHNOLOGIES, INC.
By: /s/
Thomas
N.
Konatich
Thomas
N. Konatich
Chief
Financial Officer
/s/
Bernard
Kasten
Bernard
Kasten, M.D.
KTBH:659076.2
7
Exhibit
99.1
Contact:
Thomas
N.
Konatich
SIGA
Technologies, Inc.
Chief
Financial Officer
(212)
672-9100
SIGA
REPORTS RESIGNATION OF CHIEF EXECUTIVE OFFICER
New
York,
April 3, 2006 - In anticipation of the closing of the proposed merger with
Pharmathene, Inc., announced March 14, 2006, SIGA
Technologies, Inc.
(NASDAQ:
SIGA) and Dr. Bernard L.
Kasten, its Chief Executive Officer, announced Dr. Kasten’s agreement to resign
his employment with SIGA effective the earlier of April, 30 2006 or Dr. Kasten’s
obtaining new employment. Effective immediately upon Dr. Kasten’s resignation,
Thomas N. Konatich, currently SIGA’s Chief Financial Officer, will be appointed
to serve in an additional capacity as Acting Chief Executive Officer of SIGA
until such point as the board of directors of SIGA shall select a permanent
Chief Executive Officer.
About
SIGA Technologies, Inc.
SIGA
Technologies is applying viral and bacterial genomics and sophisticated
computational modeling in the design and development of novel products for
the
prevention and treatment of serious infectious diseases, with an emphasis on
products for biological warfare defense. SIGA has the potential to become
a significant force in the discovery of vaccine and pharmaceutical agents to
fight emerging pathogens. SIGA’s product development programs emphasize
the increasingly serious problem of drug resistant bacteria. In addition
to smallpox, SIGA has antiviral programs targeting other Category A viral
pathogens, including arenaviruses (Lassa Fever Virus, Junin, Macupo, Guanarito,
and Sabia), Lymphocytic choriomeningitis virus (LCMV), Dengue, the filoviruses,
Ebola and Marburg. For more information about SIGA, please visit SIGA’s
Web site at www.siga.com.
Forward
Looking Statement Disclosure
This
press release contains certain “forward-looking statements’’ within the meaning
of the Private Securities Litigation Reform Act of 1995, as amended.
Forward-looking statements are based on management’s estimates, assumptions and
projections, and are subject to uncertainties, many of which are beyond the
control of SIGA. Actual results may differ materially from those
anticipated in any forward-looking statement.
More
detailed information about SIGA and risk factors that may affect the realization
of forward-looking statements, including the forward-looking statements in
this
press release is set forth in SIGA’s filings with the Securities and Exchange
Commission, including SIGA’s Annual Report on Form 10-K for the fiscal year
ended December 31, 2005,
and in other documents that SIGA has filed with the Commission. SIGA urges
investors and security holders to read those documents free of charge at the
Commission’s Web site at http://www.sec.gov. Interested parties may also
obtain those documents free of charge from SIGA. Forward-looking
statements speak only as to the date they are made, and except for any
obligation under the U.S. federal securities laws, SIGA undertakes no obligation
to publicly update any forward-looking statement as a result of new information,
future events or otherwise.
###